APA (7th ed.) Citation

Mateusz Małkowski, Agnieszka Almgren-Rachtan, Magdalena Olszanecka-Glinianowicz, Jerzy Chudek, & Piotr Chłosta. (2024). Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. MDPI AG.

Chicago Style (17th ed.) Citation

Mateusz Małkowski, Agnieszka Almgren-Rachtan, Magdalena Olszanecka-Glinianowicz, Jerzy Chudek, and Piotr Chłosta. Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. MDPI AG, 2024.

MLA (9th ed.) Citation

Mateusz Małkowski, et al. Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. MDPI AG, 2024.